Last reviewed · How we verify
Recombinant human follicle stimulating hormone
At a glance
| Generic name | Recombinant human follicle stimulating hormone |
|---|---|
| Also known as | Gonal-F, r-hFSH |
| Sponsor | University of California, San Diego |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site pain
- Procedural pain
- Headache
- Nausea
- Pelvic pain
- Pelvic discomfort
- Ovarian hyperstimulation syndrome
- Antepartum haemorrhage
- Fatigue
- Abortion spontaneous
- Post procedural complication
- Post procedural discomfort
Key clinical trials
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers (PHASE1)
- rFSH vs rFSH+rLH in Dydrogesterone-Based Progestin Protocol: A Prospective Study
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation (PHASE2)
- 150 IU vs. 225 IU FSH in Normal Responders: The OPTIMAL-DOSE Trial (PHASE3)
- Ovarian Hyperstimulation and Fibrin Clot Properties. (NA)
- Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |